CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1448-1454

  Sane, Shraddha A ^a   Shakya, Nishi ^a   Haq, W ^a   Gupta, Suman ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Combination therapy; Cytokine response; L. donovani; Phagocytosis; Rodents

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; MILTEFOSINE; ANTIPROTOZOAL AGENT; CPG-OLIGONUCLEOTIDE; CYTOKINE; HYDROGEN PEROXIDE; IMMUNOLOGIC FACTOR; NITRIC OXIDE; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHORYLCHOLINE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG POTENTIATION; HAMSTER; IMMUNOLOGY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; METABOLISM; PARASITOLOGY; SECRETION (PROCESS);

ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; CYTOKINES; DRUG SYNERGISM; FEMALE; HYDROGEN PEROXIDE; IMMUNOLOGIC FACTORS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHORYLCHOLINE; REACTIVE OXYGEN SPECIES; TH1 CELLS;

EID: 77954185428     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq164     Document Type: Article

References (25)

1. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6: 849-54.
2. Sundar S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006; 123: 345-52.
3. Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43: 917-24.
4. Croft S, Neal R, Pendergast W et al. The activity of alkyl phosphocholines and related derivates against Leishmania donovani. Biochem Pharmacol 1987; 36: 2633-6.
5. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6: 928-34.
6. Bogdon C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 2008; 10: 1221-34.
7. Krieg AM, Yi A, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9.
8. Kline JN, Krieg AM. CpG oligodeoxynucleotides. In: Hansel TT, Barnes PJ, eds. New Drugs for Asthma, Allergy and COPD: 31 (Progress in Respiratory Research). Basel, Switzerland: Karger, 2001; 229-32.
9. Carpentier A, Laigle-Donadey F, Zohar S et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 2006; 8: 60-6.
10. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61: 195-204.
11. Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 2003; 109: 64-71.
12. Datta N, Mukherjee S, Das L et al. Targeting of immunostimulatory DNA cure experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur J Immunol 2003; 33: 1508-18.
13. Badiee A, Jaafari MR, Samiei A et al. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol 2008; 15: 668-74.
14. Iborra S, Parody N, Abánades DR et al. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect 2008; 10: 1133-41.
15. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002; 8: 319-42.
16. Gupta S, Ramesh Sharma SC et al. Efficacy of picroliv combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. Acta Tropica 2005; 94: 41-7.
17. Jaafari MR, Badiee A, Khamesipour A et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007; 25: 6107-17.
18. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Nat Biotechnol 1984; 2: 979-84.
19. Bhatnagar S, Guru PY, Katiyar JC et al. Exploration of antileishmanial activity in heterocycles; results of their in vivo & in vitro bioevaluations. Indian J Med Res 1989; 89: 439-44.
20. Walrand S, Valeix S, Rodriguez C et al. Flow cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes. Clin Chim Acta 2003; 331: 103-10.
21. Sharma P, Raghavan SAV, Saini R et al. Ascorbate-mediated enhancement of reactive oxygen species generation from polymorphonuclear leukocytes: modulatory effect of nitric oxide. J Leukoc Biol 2004; 75: 1070-8.
22. Shrivastava JK, Misra A, Sharma P et al. Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis. Parasitology 2003; 127: 107-14.
23. Finney DJ. Probit Analysis, 3rd edn. Cambridge, UK: Cambridge University Press, 1971.
24. Murray HW. Survival of intracellular pathogens within human mononuclear phagocytes. Semin Hematol 1988; 25: 101-11.
25. Badaro R, Benson D, Eulalio MC et al. A cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1994; 173: 758-61.